eprintid: 10203576 rev_number: 7 eprint_status: archive userid: 699 dir: disk0/10/20/35/76 datestamp: 2025-01-20 11:03:56 lastmod: 2025-01-20 11:03:56 status_changed: 2025-01-20 11:03:56 type: article metadata_visibility: show sword_depositor: 699 creators_name: Yeung, Charlotte creators_name: Mccoubrey, Laura E creators_name: Basit, Abdul W title: Advances in colon-targeted drug technologies ispublished: pub divisions: UCL divisions: B02 divisions: C08 divisions: D10 divisions: G08 keywords: Artificial intelligence and machine learning, colonic targeting, gastro-resistant film coatings, mesalamine formulations, oral drug delivery systems and the large intestine note: This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. abstract: PURPOSE OF REVIEW: Herein, we present an overview of innovative oral technologies utilized in colonic drug delivery systems that have made significant translational and clinical advancements to treat inflammatory bowel disease (IBD) in recent years. RECENT FINDINGS: The colon is home to distinct physiological conditions, such as pH and microbiota, that have been exploited in the development of colonic drug delivery systems for the treatment of local and systemic diseases. However, given the intra and interindividual variability in the gastrointestinal tract of both healthy and diseased states, various systems have shown inconsistencies in targeted drug release to the colon. Recent breakthroughs have led to systems that incorporate multiple independent trigger mechanisms, ensuring drug release even if one mechanism fails due to physiological variability. Such advanced platforms have bolstered the development of oral biologics delivery, an especially promising direction given the lack of commercially available oral antibody medications for IBD. These concepts can be further enhanced by employing 3D printing which enables the personalisation of medicines. SUMMARY: Leveraging these novel technologies can accurately deliver therapeutics to the colon, allowing for treatments beyond gastrointestinal tract diseases. To realize the full potential of colonic drug delivery, it is paramount that research focuses on the clinical translatability and scalability of novel concepts. date: 2025-01 date_type: published publisher: LIPPINCOTT WILLIAMS & WILKINS official_url: https://doi.org/10.1097/mog.0000000000001064 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 2334277 doi: 10.1097/MOG.0000000000001064 medium: Print-Electronic pii: 00001574-202501000-00004 lyricists_name: Basit, Abdul lyricists_id: ABASI56 actors_name: Gaisford, Simon actors_name: Harris, Jean actors_id: SGAIS88 actors_id: JAHAR68 actors_role: owner actors_role: impersonator full_text_status: public publication: Current Opinion in Gastroenterology volume: 41 number: 1 pagerange: 9-15 pages: 7 event_location: United States issn: 0267-1379 citation: Yeung, Charlotte; Mccoubrey, Laura E; Basit, Abdul W; (2025) Advances in colon-targeted drug technologies. Current Opinion in Gastroenterology , 41 (1) pp. 9-15. 10.1097/MOG.0000000000001064 <https://doi.org/10.1097/MOG.0000000000001064>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10203576/1/Advances%20in%20colon-targeted%20drug%20technologies.pdf